---
title: Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue
nct_id: NCT00958503
overall_status: COMPLETED
phase: PHASE1
sponsor: Psyadon Pharma
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Belgium
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00958503.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00958503"
ct_last_update_post_date: 2015-03-25
last_seen_at: "2026-05-12T06:16:33.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue

**Official Title:** A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 14-Day Repeated-Dose Administration of Thiamphenicol (RUX 122) in Healthy Subjects

**NCT ID:** [NCT00958503](https://clinicaltrials.gov/study/NCT00958503)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Psyadon Pharma
- **Collaborators:** SGS Life Sciences, a division of SGS Belgium NV
- **Conditions:** Healthy
- **Start Date:** 2007-07
- **Completion Date:** 2008-04
- **CT.gov Last Update:** 2015-03-25

## Brief Summary

The purpose of this study is to determine if two-weeks of dosing with thiamphenicol is safe and is able to change the levels of certain pre-specified biomarkers in nervous tissue taken from the nasal passages.

## Detailed Description

Thiamphenicol has been proposed to increase the levels of the excitatory amino acid transporter 2 (EAAT2) in the nervous tissue. This study evaluated the ability of two weeks of treatment with thiamphenicol to increase EAAT2 in a nasal biopsy as a surrogate of brain nervous tissue.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* normal volunteers

Exclusion Criteria:

* less than 18 years
* older than 55 years
```

## Arms

- **Placebo** (PLACEBO_COMPARATOR) — Placebo
- **Thiamphenicol** (ACTIVE_COMPARATOR) — Active comparator

## Interventions

- **Thiamphenicol** (DRUG) — 750 and 1500 mg/day;tablets
- **Placebo** (DRUG) — Matched tablets without active ingredient

## Primary Outcomes

- **Amount of EAAT2 RNA in nasal biopsy** _(time frame: Two weeks)_

## Locations (1)

- SGS Research Unit - Stuivenberg, Antwerp, Belgium

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sgs research unit - stuivenberg|antwerp||belgium` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00958503.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00958503*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*